BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16551966)

  • 1. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).
    Robak T; Blonski JZ; Gora-Tybor J; Jamroziak K; Dwilewicz-Trojaczek J; Tomaszewska A; Konopka L; Ceglarek B; Dmoszynska A; Kowal M; Kloczko J; Stella-Holowiecka B; Sulek K; Calbecka M; Zawilska K; Kuliczkowski K; Skotnicki AB; Warzocha K; Kasznicki M;
    Blood; 2006 Jul; 108(2):473-9. PubMed ID: 16551966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
    Robak T; Boński JZ; Kasznicki M; Góra-Tybor J; Hellmann A; Konopka L; Dmoszyńska A; Dwilewicz-Trojaczek J; Wołowiec D;
    Eur J Haematol; 2002 Jul; 69(1):27-36. PubMed ID: 12270059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
    Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dwilewicz-Trojaczek J; Stella-Hołowiecka B; Wołowiec D
    Hematol J; 2002; 3(5):244-50. PubMed ID: 12391542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
    Robak T; Błoński JZ; Kasznicki M; Góra-Tybor I; Dwilewicz-Trojaczek J; Boguradzki P; Konopka L; Ceglarek B; Sułek J; Kuliczkowski K; Wołowiec D; Stella-Hołowiecka B; Skotnicki AB; Nowak W; Moskwa-Sroka B; Dmoszyńska A; Calbecka M
    Leukemia; 2001 Oct; 15(10):1510-6. PubMed ID: 11587207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
    Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
    Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.
    Robak T; Blonski JZ; Gora-Tybor J; Calbecka M; Dwilewicz-Trojaczek J; Boguradzki P; Dmoszynska A; Kowal M; Kloczko J; Piszcz J; Stella-Holowiecka B; Sulek K; Kuliczkowski K; Potoczek S; Warzocha K; Lech-Maranda E; Skotnicki AB; Piotrowska M; Moskwa A; Zawilska K; Jamroziak K
    Leuk Lymphoma; 2014 Mar; 55(3):606-10. PubMed ID: 23721512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
    J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.
    Robak T; Bloński JZ; Kasznicki M; Blasińska-Morawiec M; Krykowski E; Dmoszyńska A; Mrugala-Spiewak H; Skotnicki AB; Nowak W; Konopka L; Ceglarek B; Maj S; Dwilewicz-Trojaczek J; Hellmann A; Urasiński I; Zdziarska B; Kotlarek-Haus S; Potoczek S; Grieb P
    Blood; 2000 Oct; 96(8):2723-9. PubMed ID: 11023504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
    Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).
    Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dmoszyńska A; Wojtaszko M; Skotnicki AB; Nowak W; Hellmann A; Lewandowski K; Zdziarska B; Konopka L; Ceglarek B; Dwilewicz-Trojaczek J; Boguradzki P; Kuliczkowski K; Sułek K; Warzocha K
    Med Sci Monit; 2005 Oct; 11(10):PI71-9. PubMed ID: 16192912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Munir T; Howard DR; McParland L; Pocock C; Rawstron AC; Hockaday A; Varghese A; Hamblin M; Bloor A; Pettitt A; Fegan C; Blundell J; Gribben JG; Phillips D; Hillmen P
    Leukemia; 2017 Oct; 31(10):2085-2093. PubMed ID: 28216660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.
    Robak T; Błoński J; Skotnicki AB; Piotrowska M; Wróbel T; Rybka J; Kłoczko J; Bołkun Ł; Budziszewska BK; Walczak U; Uss A; Fidecka M; Smolewski P
    Eur J Haematol; 2018 May; 100(5):465-474. PubMed ID: 29427355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
    Robak T; Błoński JZ; Urbańska-Ryś H; Błasińska-Morawiec M; Skotnicki AB
    Leukemia; 1999 Apr; 13(4):518-23. PubMed ID: 10214856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
    Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
    Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
    Kobylinska A; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
    Oncol Rep; 2004 Mar; 11(3):699-705. PubMed ID: 14767525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
    Abrisqueta P; Villamor N; Terol MJ; González-Barca E; González M; Ferrà C; Abella E; Delgado J; García-Marco JA; González Y; Carbonell F; Ferrer S; Monzó E; Jarque I; Muntañola A; Constants M; Escoda L; Calvo X; Bobillo S; Montoro JB; Montserrat E; Bosch F
    Blood; 2013 Dec; 122(24):3951-9. PubMed ID: 24124086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
    Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.